Research ArticleOMERACT 12 — International Consensus Conference on Outcome Measures in Rheumatology, Budapest, Hungary, May 7–11, 2014

Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12

Lilian H. van Tuyl, Martina Sadlonova, Bev Davis, Caroline Flurey, Niti Goel, Sarah E. Hewlett, Catherine L. Hill, Wijnanda Hoogland, John R. Kirwan, Dirkjan van Schaardenburg, Marieke Scholte-Voshaar, Josef S. Smolen, Tanja Stamm, George A. Wells and Maarten Boers
The Journal of Rheumatology January 2016, 43 (1) 203-207; DOI: https://doi.org/10.3899/jrheum.141113

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Main themes of rheumatoid arthritis remission. The 3 main themes (symptoms, impact, and normality) are underpinned by a theme of influential factors, with an overarching theme of assessment issues.

Tables

  • Table 1.

    Preliminary survey results: respondent demographics.

    TotalAmsterdamViennaOMERACT PRP
    N4916285
    Age, yrs, mean (SD)56.4 (12.7)63.8 (8.3)52.2 (13.9)55 (0.6)
    Female, %787575100
    At least 1 comorbidity (%)57695440
    Disease duration, yrs, mean (SD)12.4 (10)11.8 (7)9.8 (10)29.0 (3)
    Currently in remission, self-perceived, %476943100

    • PRP: patient research partners.

  • Table 2.

    Top 3 features by frequency (%), irrespective of the first, second, or third position (preliminary data).

    DomainFrequency in Top 3, n = 46*Amsterdam, n = 14Vienna, n = 27PRP, n = 5
    Pain28 (61)5 (36)19 (70)4 (80)
    Independence11 (24)2 (14)7 (26)2 (40)
    Fatigue10 (22)2 (14)6 (22)2 (40)
    Leisure/sports9 (20)4 (29)5 (19)0 (0)
    Physical functioning7 (15)2 (14)4 (15)1 (20)
    Being mobile6 (13)1 (7)5 (19)0 (0)
    Social life6 (13)5 (36)1 (4)0 (0)
    Ability to work6 (13)3 (21)3 (11)0 (0)
    Swelling5 (11)1 (7)3 (11)1 (20)
    Mood5 (11)0 (0)5 (19)0 (0)
    Use of DMARD5 (11)2 (14)3 (11)0 (0)
    Daily activities5 (11)1 (7)3 (11)1 (20)

    • ↵* Three respondents did not provide the top 3 features. DMARD: disease-modifying antirheumatic drugs; PRP: patient research partners.

  • Table 3.

    Frequency of features ranked as essential (%) for 49 respondents (preliminary data).

    FeatureNot ImportantRanking ImportantEssential
    Physical functioning1 (2.1)15 (31.3)32 (66.7)
    Mobility2 (4.2)18 (37.5)28 (58.3)
    Independence4 (8.3)17 (35.4)27 (56.3)
    Pain5 (10.4)17 (35.4)26 (54.2)
    Daily activities2 (4.2)24 (50.0)22 (45.8)
    Mental power8 (16.7)18 (37.5)22 (45.8)
    Fine motor skills4 (8.3)24 (50.0)20 (41.7)
    Flares8 (16.7)21 (43.8)19 (39.6)
    Swelling5 (10.4)26 (54.2)17 (35.4)
    Grip5 (10.4)26 (54.2)17 (35.4)
    Family role5 (10.4)26 (54.2)17 (35.4)
    Leisure1 (2.1)31 (64.6)16 (33.3)
  • Table 4.

    Research agenda for the patient perspective on remission in rheumatoid arthritis.

    • Survey: Increase sample of respondents to rate domains for importance by:

      • — involving countries outside the current scope

      • — including respondents with both early and late disease

      • — including respondents with both erosive and nonerosive disease

    • Seek collaboration with the RA flare and RAID groups

    • Compare RAID domains with remission domains

    • Consider collecting additional identified domains alongside the RAID

    • Investigate overlap between patient global assessment of disease activity and other important PRO, specifically pain and fatigue

    • RA: rheumatoid arthritis; RAID: RA Impact of Disease methodology; PRO: patient-reported outcomes.

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

OMERACT
RHEUMATOID ARTHRITIS
REMISSION
PATIENT-REPORTED OUTCOME
PATIENT PERSPECTIVE

Keywords